GlassScriptPhysician profile
Keely M Cox
NPI 1952955502
$4,915.22
in general payments reported to CMS, 2019-2025
34 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,003 · 2022: $1,185 · 2023: $814 · 2024: $879 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.79 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $333.21 | 2021-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $255.24 | 2022-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $234.98 | 2021-2023 | Vumerity, Tysabri, Plegridy |
| Sk Life Science, INC. | $227.46 | 2021-2022 | |
| Genentech USA, INC. | $211.10 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $206.83 | 2021 | |
| Genentech, INC. | $198.85 | 2023-2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $188.50 | 2024 | |
| Argenx US, INC. | $173.95 | 2025 | Vyvgart |
| Kyowa Kirin, INC. | $154.44 | 2021-2022 | |
| Pfizer INC. | $139.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $108.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.83 | 2022 | |
| Lilly USA, LLC | $76.57 | 2023-2024 | Reyvow, Emgality |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $75.62 | 2021 | |
| Neurocrine Biosciences, INC. | $66.39 | 2022-2023 | Ongentys, Ingrezza |
| Livanova USA, INC. | $65.45 | 2021 | |
| Amgen INC. | $58.14 | 2022-2023 | Aimovig |
| Ipsen Biopharmaceuticals, INC | $49.36 | 2023 | Dysport |
| Acadia Pharmaceuticals INC | $48.97 | 2021 | |
| Upsher-Smith Laboratories LLC | $48.59 | 2022-2023 | |
| Celgene Corporation | $45.57 | 2024 | Zeposia |
| Sunovion Pharmaceuticals INC. | $43.99 | 2021-2022 | |
| Ucb, INC. | $43.44 | 2022-2024 | Briviact |
| Amneal Pharmaceuticals LLC | $42.56 | 2021-2022 | |
| Acorda Therapeutics, INC | $39.08 | 2021-2024 | Ampyra, Inbrija |
| Alexion Pharmaceuticals, INC. | $34.39 | 2025 | Ultomiris |
| Genzyme Corporation | $27.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.76 | 2021 | |
| Csl Behring | $21.44 | 2021 | |
| Ge Healthcare | $16.33 | 2022 | |
| Neurelis, INC. | $14.75 | 2021 | |
| Lundbeck LLC | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keely Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.